Experiment Protocol Biomedical Engineer in Belgium Brussels –Free Word Template Download with AI

This experiment protocol outlines the procedures for evaluating a novel wearable biosensor designed for continuous glucose monitoring (CGM) in patients with Type 2 Diabetes Mellitus (T2DM). The study will be conducted in Brussels, Belgium, leveraging the city's advanced healthcare infrastructure and research facilities. As a Biomedical Engineer, the principal investigator is responsible for ensuring the technical integrity, safety, and regulatory compliance of the experiment.

The primary objective is to assess the accuracy, reliability, and user-friendliness of the biosensor compared to standard finger-prick glucose tests. Secondary objectives include evaluating patient comfort, device durability, and data transmission efficiency.

All procedures will adhere to the ethical guidelines set forth by the European Union's General Data Protection Regulation (GDPR) and the Belgian Law of 7 May 2004 on the Protection of the Individual with Regard to the Processing of Personal Data. The protocol has been reviewed and approved by the Ethics Committee of the Université Libre de Bruxelles (ULB).

Informed consent will be obtained from all participants prior to their involvement in the study. Participants will be provided with detailed information about the study's purpose, procedures, potential risks, and benefits. They will be informed of their right to withdraw from the study at any time without penalty.

The study will employ a randomized controlled trial (RCT) design. Participants will be randomly assigned to one of two groups:

• Intervention Group: Participants will use the novel wearable biosensor for continuous glucose monitoring.
• Control Group: Participants will use standard finger-prick glucose tests.

The study duration will be 12 weeks, with follow-up assessments at 4, 8, and 12 weeks.

Inclusion Criteria:

• Adults aged 18-75 years.
• Diagnosed with Type 2 Diabetes Mellitus for at least 1 year.
• Currently using insulin or oral hypoglycemic agents.
• Residing in Brussels, Belgium, for at least 6 months.
• Willing and able to provide informed consent.

Exclusion Criteria:

• Pregnant or breastfeeding women.
• History of severe hypoglycemia unawareness.
• Known allergies to adhesive materials.
• Participation in another clinical trial within the past 3 months.

5.1 Baseline Assessment:

At the beginning of the study, all participants will undergo a baseline assessment, including:

• Medical history review.
• Physical examination.
• Blood glucose level measurement.
• HbA1c test.

5.2 Device Training:

Participants in the intervention group will receive training on how to use the wearable biosensor. This will include instructions on device placement, data interpretation, and troubleshooting.

5.3 Data Collection:

Participants will be instructed to record their glucose levels using the assigned method (wearable biosensor or finger-prick test) at least four times daily. Data will be transmitted to a secure server for analysis.

5.4 Follow-Up Assessments:

At 4, 8, and 12 weeks, participants will return for follow-up assessments, including:

• Review of glucose data.
• Assessment of device comfort and usability.
• Discussion of any adverse events.

Data will be analyzed using statistical software (e.g., SPSS). Primary outcomes will include:

• Accuracy of glucose readings compared to standard finger-prick tests.
• Reliability of the wearable biosensor over time.

Secondary outcomes will include:

• Patient satisfaction and comfort.
• Device durability and data transmission efficiency.

Participants will be monitored for any adverse events related to the use of the wearable biosensor. Common adverse events may include skin irritation or discomfort. Serious adverse events will be reported to the Ethics Committee and relevant regulatory authorities in Belgium.

This experiment protocol outlines a comprehensive approach to evaluating a novel wearable biosensor for continuous glucose monitoring in Type 2 Diabetes patients in Brussels, Belgium. As a Biomedical Engineer, the principal investigator is committed to ensuring the highest standards of scientific rigor, ethical conduct, and patient safety throughout the study.